Clinical Trials Browser

HER2/Neu Negative × 16-fluoroestradiol × 90 days × Clear all

NCT02398773 2026-03-18

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Phase 2 Active not recruiting

HER2/Neu Negative